Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer

Editorial Office

Translational Lung Cancer Research
Correspondence to: Editorial Office. Translational Lung Cancer Research. Email: editor@tlcr.org.

Submitted Mar 20, 2022. Accepted for publication Mar 21, 2022.
doi: 10.21037/tlcr-2022-1
View this article at: https://dx.doi.org/10.21037/tlcr-2022-1

Erratum to: Transl Lung Cancer Res 2021;10:4368-79

The article (1) titled “Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer” (doi: 10.21037/tlcr-21-682), unfortunately contained a mistake in the first affiliation of Zhen Wang1,2 and Yong Song1,5#. The correct authors’ affiliation 1 is listed below:

1The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Therefore, the correct author information is as follows:

Zhen Wang1,2, Lingyun Wei1, Jing Li2, Han Zhou3, Si Li4, Dongsheng Chen5, Yangyang Yu5, Lele Zhao5, Xixu Zhu2#, Yong Song1,5#

1The First School of Clinical Medicine, Southern Medical University, Guangzhou, China; 2Department of Radiation Oncology, Jinling Hospital, Nanjing, China; 3Department of Cardiothoracic Surgery, School of Medicine, Nanjing University/General Hospital of Eastern Theater Command, Nanjing, China; 4The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Sincere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China; 5Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China

The authors regret the error.

Click here to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References


Cite this article as: Editorial Office. Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res 2022;11(3):504-505. doi: 10.21037/tlcr-2022-1